Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial

INTRODUCTION: Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may decrease progression of chronic kidney disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Leehey, David J, Carlson, Kimberly, Reda, Domenic J, Craig, Ian, Clise, Christina, Conner, Todd A, Agarwal, Rajiv, Kaufman, James S, Anderson, Robert J, Lammie, Douglas, Huminik, Jeffrey, Polzin, Linda, McBurney, Conor, Huang, Grant D, Emanuele, Nicholas V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370537/
https://www.ncbi.nlm.nih.gov/pubmed/34400461
http://dx.doi.org/10.1136/bmjopen-2021-053019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370537/
https://www.ncbi.nlm.nih.gov/pubmed/34400461
http://dx.doi.org/10.1136/bmjopen-2021-053019

Ejemplares similares